New Data in nAMD: What Does the Future Hold?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Evolving Treatment Paradigms in nAMD

Current Anti-VEGF Therapy for nAMD: Benefits and Limitations

Unmet Needs of Anti-VEGF Therapy

Future Considerations in nAMD Treatment

New Treatments in Development

Molecular Characteristics of Brolucizumab

Molecular Sizes of Anti-VEGF Agents

Single-Chain Variable Fragment

Potential Clinical Implications of Molecular Characteristics of Brolucizumab

Clinical Relevance of Brolucizumab Trial Designs

HAWK and HARRIER Trial Design

HAWK and HARRIER Trial Design: Matched Comparison Phase

Potential Clinical Relevance of Study Design

Clinical Trial Results: HAWK and HARRIER

HAWK and HARRIER Trial Design

Proportion of Patients Maintaining Every 12 Week Dosing of Brolucizumab at 48 Weeks

Central Subfield Thickness

Relevance of Clinical Trial Results

Emerging Therapies in nAMD Treatment

Designed Ankyrin Repeat Protein (DARPin®): Abicipar Pegol

Abicipar Pegol: REACH Phase 2 Clinical Study Visual Acuity Results

Angiopoietins as a Target in nAMD: Nesvacumab

Squalamine Eyedrops

Gene Therapy in nAMD

Gene Therapy in nAMD: Therapeutic Aim

Impact of New Agents on Clinical Practice

Improvements in Outcomes: Advances to Reduce Treatment Burden

Clinical Trials of Brolucizumab: Reduction in Anatomic Thickness With a Less Frequent Injection Frequency

BCVA Change From Baseline Over Time

Other Agents and Approaches in the Pipeline

Abbreviations

Abbreviations (cont)